Back to Directory

Charlotte Perlowski

Email

Phone

Institution

FHI 360

Role

Staff

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

Locality

United States

IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30073

Research Area

Complications & Comorbidities

Study Status

Concluded

Locality

United States

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30074

Research Area

Complications & Comorbidities

Study Status

Participants Off Study and Primary Analysis Completed

Locality

United States

P1114: Safety and Immunogenicity of an RSV Vaccine cps2

DAIDS Number

11948

Research Area

Complications & Comorbidities

Study Status

Concluded

Locality

United States

P1115: Very Early Intensive Tx on HIV-Infected Infants

DAIDS Number

11954

Research Area

Cure

Study Status

Enrolling

Locality

US & Non-US

Show All